JP2017225455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017225455A5 JP2017225455A5 JP2017151394A JP2017151394A JP2017225455A5 JP 2017225455 A5 JP2017225455 A5 JP 2017225455A5 JP 2017151394 A JP2017151394 A JP 2017151394A JP 2017151394 A JP2017151394 A JP 2017151394A JP 2017225455 A5 JP2017225455 A5 JP 2017225455A5
- Authority
- JP
- Japan
- Prior art keywords
- infection
- agent
- hev
- niv
- infected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 8
- 241000893570 Hendra henipavirus Species 0.000 claims 7
- 241001668225 Cedar virus Species 0.000 claims 6
- 241000526636 Nipah henipavirus Species 0.000 claims 6
- 108010044090 Ephrin-B2 Proteins 0.000 claims 4
- 102000006396 Ephrin-B2 Human genes 0.000 claims 3
- 208000000464 Henipavirus Infections Diseases 0.000 claims 3
- 230000000120 cytopathologic effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261667194P | 2012-07-02 | 2012-07-02 | |
| US61/667,194 | 2012-07-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520648A Division JP6246199B2 (ja) | 2012-07-02 | 2013-07-02 | パラミクソウイルスおよび使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149331A Division JP2019205475A (ja) | 2012-07-02 | 2019-08-16 | パラミクソウイルスおよび使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017225455A JP2017225455A (ja) | 2017-12-28 |
| JP2017225455A5 true JP2017225455A5 (enExample) | 2018-05-17 |
Family
ID=49882591
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520648A Active JP6246199B2 (ja) | 2012-07-02 | 2013-07-02 | パラミクソウイルスおよび使用方法 |
| JP2017151394A Pending JP2017225455A (ja) | 2012-07-02 | 2017-08-04 | パラミクソウイルスおよび使用方法 |
| JP2019149331A Pending JP2019205475A (ja) | 2012-07-02 | 2019-08-16 | パラミクソウイルスおよび使用方法 |
| JP2022002835A Pending JP2022050586A (ja) | 2012-07-02 | 2022-01-12 | パラミクソウイルスおよび使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520648A Active JP6246199B2 (ja) | 2012-07-02 | 2013-07-02 | パラミクソウイルスおよび使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149331A Pending JP2019205475A (ja) | 2012-07-02 | 2019-08-16 | パラミクソウイルスおよび使用方法 |
| JP2022002835A Pending JP2022050586A (ja) | 2012-07-02 | 2022-01-12 | パラミクソウイルスおよび使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20150191702A1 (enExample) |
| EP (1) | EP2866829B1 (enExample) |
| JP (4) | JP6246199B2 (enExample) |
| AU (3) | AU2013286866B2 (enExample) |
| CA (1) | CA2877948C (enExample) |
| WO (1) | WO2014008263A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014008263A2 (en) | 2012-07-02 | 2014-01-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Paramyxovirus and methods of use |
| WO2022232218A1 (en) * | 2021-04-27 | 2022-11-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Recombinant cedar virus chimeras |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5759573A (en) | 1993-04-22 | 1998-06-02 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| WO1995007994A2 (en) | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| RO116341B1 (ro) | 1993-11-16 | 2001-01-30 | Depotech Corp La Jolia | Lipozom multivezicular si procedeu de obtinere a acestuia |
| US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
| JP4303315B2 (ja) | 1994-05-09 | 2009-07-29 | オックスフォード バイオメディカ（ユーケー）リミテッド | 非交差性レトロウイルスベクター |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| EP0953052B1 (en) | 1996-05-06 | 2009-03-04 | Oxford BioMedica (UK) Limited | Crossless retroviral vectors |
| WO1999018792A1 (en) | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
| JP2007505618A (ja) * | 2003-09-22 | 2007-03-15 | インスティティ・パスツール | ニパウイルスの検出方法及びヘニパウイルスに対する免疫保護を提供する方法 |
| WO2006115843A2 (en) * | 2005-04-25 | 2006-11-02 | Merial Limited | Nipah virus vaccines |
| EP2362909A4 (en) * | 2008-09-30 | 2012-10-10 | Zirus Inc | MAMMALIAN GENES INVOLVED IN INFECTION |
| WO2014008263A2 (en) | 2012-07-02 | 2014-01-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Paramyxovirus and methods of use |
-
2013
- 2013-07-02 WO PCT/US2013/049069 patent/WO2014008263A2/en not_active Ceased
- 2013-07-02 JP JP2015520648A patent/JP6246199B2/ja active Active
- 2013-07-02 AU AU2013286866A patent/AU2013286866B2/en active Active
- 2013-07-02 EP EP13813542.1A patent/EP2866829B1/en active Active
- 2013-07-02 US US14/412,533 patent/US20150191702A1/en not_active Abandoned
- 2013-07-02 CA CA2877948A patent/CA2877948C/en active Active
-
2016
- 2016-06-13 US US15/180,544 patent/US10227664B2/en active Active
-
2017
- 2017-08-04 JP JP2017151394A patent/JP2017225455A/ja active Pending
-
2018
- 2018-05-29 AU AU2018203773A patent/AU2018203773B2/en active Active
-
2019
- 2019-03-12 US US16/351,380 patent/US11242572B2/en active Active
- 2019-08-16 JP JP2019149331A patent/JP2019205475A/ja active Pending
-
2020
- 2020-09-04 AU AU2020227113A patent/AU2020227113B2/en active Active
-
2022
- 2022-01-12 JP JP2022002835A patent/JP2022050586A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Activation of Kaposi's sarcoma-associated herpesvirus (KSHV) by inhibitors of class III histone deacetylases: identification of sirtuin 1 as a regulator of the KSHV life cycle | |
| Cilloniz et al. | Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection | |
| Walpita et al. | A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model | |
| Goujon et al. | Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection | |
| Fu et al. | MicroRNA miR-21 attenuates human cytomegalovirus replication in neural cells by targeting Cdc25a | |
| US7512809B2 (en) | Attenuated computer virus vaccine | |
| EA201892648A1 (ru) | Вирусы пичинде с трехсегментным геномом в качестве векторных вакцин | |
| Thornburg et al. | Respiratory syncytial virus regulates human microRNAs by using mechanisms involving beta interferon and NF-κB | |
| Uppal et al. | Chromatinization of the KSHV genome during the KSHV life cycle | |
| JP2016028035A5 (enExample) | ||
| Sudaryatma et al. | Bovine respiratory syncytial virus infection enhances Pasteurella multocida adherence on respiratory epithelial cells | |
| Strive et al. | The non-pathogenic Australian rabbit calicivirus RCV-A1 provides temporal and partial cross protection to lethal Rabbit Haemorrhagic Disease Virus infection which is not dependent on antibody titres | |
| MX383596B (es) | Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas. | |
| Safronetz et al. | In vitro and in vivo activity of ribavirin against Andes virus infection | |
| EP3474888A4 (en) | ADOPTIVE CELL TRANSFER AND ONCOLYTIC VIRUS COMBINATION THERAPY | |
| Cubas-Gaona et al. | Exacerbated apoptosis of cells infected with infectious bursal disease virus upon exposure to interferon alpha | |
| RU2015133205A (ru) | Использование ингибиторов inos для повышения урожая вирусов в культуре | |
| Portugal et al. | Modulation of type I interferon signaling by African swine fever virus (ASFV) of different virulence L60 and NHV in macrophage host cells | |
| EP4061417A4 (en) | VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES | |
| Chavez-Calvillo et al. | The structure-to-function relationships of gammaherpesvirus-encoded long non-coding RNAs and their contributions to viral pathogenesis | |
| MX2022003068A (es) | Metodos para bloquear la infeccion por asfv mediante la interrupcion de receptores celulares. | |
| JP2017225455A5 (enExample) | ||
| Cox et al. | Priming with rhinovirus protects mice against a lethal pulmonary coronavirus infection | |
| Feitelson et al. | Hepatitis B x (HBx) as a component of a functional cure for chronic hepatitis B | |
| EP3714044A4 (en) | COMPOSITIONS AND PROCEDURES TO INCREASE THE PRODUCTION, GROWTH, SPREAD OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICIENCY OF INTERFERON-SENSITIVE VIRUSES |